Stockscreener 앱 받기
7.7008
4.36%
-0.3592
Iteos Therapeutics Inc 주식(ITOS)의 최신 뉴스
JPMorgan Chase & Co. Purchases 5,368 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 21.1% - MarketBeat
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy - MSN
iTeos Therapeutics' (ITOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
(ITOS) On The My Stocks Page - Stock Traders Daily
Barclays PLC Has $1.16 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Invivyd (NASDAQ:IVVD) vs. iTeos Therapeutics (NASDAQ:ITOS) Head-To-Head Comparison - Defense World
Iteos Therapeutics advances anti-TREM2 monoclonal antibody toward IND filing - BioWorld Online
iTeos Therapeutics Plans 2025 Data Presentation on Therapies - TipRanks
iTeos Therapeutics to raise $120 million via registered direct offering - MSN
Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Informazione.it
iTeos annonce ses priorités stratégiques et ses étapes clés prévues pour 2025 - GlobeNewswire Inc.
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
iTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
iTeos Unveils Ambitious 2025 Cancer Drug Pipeline: Multiple Phase 2 Readouts, $684M Cash Runway - StockTitan
iTeos Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Trading (ITOS) With Integrated Risk Controls - Stock Traders Daily
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Geode Capital Management LLC - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Trimmed by Franklin Resources Inc. - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Holdings Lessened by Barclays PLC - Defense World
Reviewing Calidi Biotherapeutics (NYSE:CLDI) & iTeos Therapeutics (NASDAQ:ITOS) - Defense World
State Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
State Street Corp Increases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Trend Tracker for (ITOS) - Stock Traders Daily
Wells Fargo & Company Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo - Yahoo Finance
iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $19.00 by Analysts at Wells Fargo & Company - MarketBeat
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy - MSN
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report - BioCentury
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
Merck & Co. Calls Time On Flop TIGIT And LAG-3 Programs - News & Insights
Charles Schwab Investment Management Inc. Buys 8,397 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright - Defense World
Wedbush Reaffirms “Outperform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Earns Buy Rating from HC Wainwright - MarketBeat
Iteos Therapeutics stock hits 52-week low at $7.52 - Investing.com India
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data - BioSpace
Inupadenant shows promise in NSCLC Phase 2 trial results - Investing.com
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial - GlobeNewswire
ITeos Therapeutics, Inc. Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - Marketscreener.com
Intech Investment Management LLC Invests $154,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
RA Capital Management L.P. Cuts Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
(ITOS) Technical Data - Stock Traders Daily
Quest Partners LLC Has $113,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Vestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Victory Capital Management Inc. Lowers Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Algert Global LLC - MarketBeat
iTeos to Participate in Upcoming Investor Conferences - GlobeNewswire
iTeos Therapeutics to Present at Evercore and Piper Sandler Healthcare Conferences | ITOS Stock News - StockTitan
0.96%
8.55%
자본화:
|
볼륨(24시간):